MX9806182A - Medicamento antiglucocorticoide. - Google Patents
Medicamento antiglucocorticoide.Info
- Publication number
- MX9806182A MX9806182A MX9806182A MX9806182A MX9806182A MX 9806182 A MX9806182 A MX 9806182A MX 9806182 A MX9806182 A MX 9806182A MX 9806182 A MX9806182 A MX 9806182A MX 9806182 A MX9806182 A MX 9806182A
- Authority
- MX
- Mexico
- Prior art keywords
- aliphatic
- pheromones
- mammalian cells
- carbon atoms
- nonsteroidal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Securing Of Glass Panes Or The Like (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
La invencion tiene relacion con la Medicina y la Veterinaria, concretamente con los preparados medicinales antiglucocorticoides de naturaleza no esteroide. La tarea de la invencion es crear una clase nueva de preparados medicinales con baja toxicidad y alta eficiencia para regular la sensibilidad de las células de los mamíferos de la accion de las hormonas glucocorticoides. Es nueva la aplicacion de la feromona de insectos de naturaleza no esteroides o de su análogo sintético o derivado (que representa un alcohol alifático no saturado con una cadena larga, aldehído o éter) para inhibir selectivamente la accion de las hormonas glucocorticoides sobre las células de los mamíferos. La longitud de la cadena lineal de hidrocarburo de cualquiera de los elementos indicados está en los límites de 10 a 21 átomos de carbono. Además, para aumentar el efecto terapéutico es posible aplicar, al mismo tiempo, dos o más feromonas y/o sus análogos sintéticos y derivados, elegidos por el principio, esencialmente, del diverso carácter hidrofobo, proporcional a las longitudes de las cadenas alifáticas lineales de los hidrocarburos: la diferencia en las longitudes de las cadenas indicadas debe ser no menor de cinco. Se citan ejemplos para obtener medicamentos y los resultados de los experimentos comparativos que ha mostrado su alta eficacia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU96101194/14A RU2125446C1 (ru) | 1996-01-31 | 1996-01-31 | Антиглюкокортикоидное лекарственное средство |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9806182A true MX9806182A (es) | 1998-10-31 |
Family
ID=20175968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9806182A MX9806182A (es) | 1996-01-31 | 1998-07-31 | Medicamento antiglucocorticoide. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5965623A (es) |
| EP (1) | EP0896819A4 (es) |
| JP (1) | JPH11504946A (es) |
| KR (1) | KR100347862B1 (es) |
| CN (1) | CN1213964A (es) |
| AU (1) | AU710479B2 (es) |
| BG (1) | BG102709A (es) |
| BR (1) | BR9612470A (es) |
| CA (1) | CA2244985A1 (es) |
| CZ (1) | CZ160598A3 (es) |
| EE (1) | EE9800209A (es) |
| GE (1) | GEP20001955B (es) |
| HU (1) | HUP9900504A2 (es) |
| LT (1) | LT4441B (es) |
| LV (1) | LV12177B (es) |
| MD (1) | MD1430B1 (es) |
| MX (1) | MX9806182A (es) |
| NO (1) | NO983508D0 (es) |
| PL (1) | PL187564B1 (es) |
| RU (1) | RU2125446C1 (es) |
| SI (1) | SI9620053A (es) |
| SK (1) | SK65598A3 (es) |
| UA (1) | UA48212C2 (es) |
| WO (1) | WO1997027845A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001039766A2 (en) * | 1999-12-01 | 2001-06-07 | Alydar Pharmaceuticals Ltd. | Screening invertebrate pheromones for therapeutic activity |
| US6548706B2 (en) * | 1999-12-23 | 2003-04-15 | Aerojet Fine Chemicals Llc | Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines |
| WO2002072809A1 (en) * | 2001-03-12 | 2002-09-19 | Alydar Pharmaceuticals, Inc. | Screening non-peptide, non-steroid invertebrate pheromone compounds for mitogen-activated protein kinase modulating activity |
| US6806293B1 (en) | 2001-03-12 | 2004-10-19 | Darley Pharmaceuticals Ltd | Use of pheromone compounds having MAP kinase modulating activity |
| WO2003092614A2 (en) * | 2002-05-02 | 2003-11-13 | Hickle Randall S | Lipid removal from the body |
| US6752649B2 (en) * | 2002-11-07 | 2004-06-22 | Xentris, Llc | Illuminated indicia power supply apparatus and method of manufacture |
| DE10335845B4 (de) * | 2003-05-09 | 2006-08-31 | Müller, Martina, Dr.med. | Pheromone als Antikrebsmittel |
| WO2010017177A1 (en) * | 2008-08-06 | 2010-02-11 | The Trustees Of The University Of Pennsylvania | Ultrasonically induced release from polymer vesicles |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US161926A (en) | 1875-04-13 | Improvement in ink-wells | ||
| US2900756A (en) * | 1958-12-09 | 1959-08-25 | Jacobson Martin | Attractants for the gypsy moth |
| EP0149847A3 (en) * | 1983-12-26 | 1989-11-08 | Eisai Co., Ltd. | Therapeutic and preventive agent containing dolichol |
| JPH0759504B2 (ja) * | 1986-01-23 | 1995-06-28 | エーザイ株式会社 | ポリプレニルアルコ−ル含有注射剤 |
| US5019569A (en) * | 1986-11-03 | 1991-05-28 | Ortho Pharmaceutical Corporation | Reversal of glucocorticoid-induced skin atrophy |
| US4740627A (en) * | 1987-05-21 | 1988-04-26 | Phillips Petroleum Company | Synthesis of E,Z-11-tetradecen-1-al |
| DE68902753T2 (de) | 1988-02-29 | 1993-01-21 | Pfizer | Mittel zur erhoehung des transdermalen penetrationsflusses. |
| US5190978A (en) * | 1989-09-29 | 1993-03-02 | Dai-Ichi Kogyo Seiyaku Co. Ltd. | Carcinostatic compositions and methods |
-
1996
- 1996-01-02 UA UA98074187A patent/UA48212C2/uk unknown
- 1996-01-31 RU RU96101194/14A patent/RU2125446C1/ru not_active IP Right Cessation
- 1996-02-01 MD MD98-0171A patent/MD1430B1/ro unknown
- 1996-02-01 CA CA002244985A patent/CA2244985A1/en not_active Abandoned
- 1996-02-01 AU AU46363/96A patent/AU710479B2/en not_active Ceased
- 1996-02-01 PL PL96322596A patent/PL187564B1/pl unknown
- 1996-02-01 EE EE9800209A patent/EE9800209A/xx unknown
- 1996-02-01 HU HU9900504A patent/HUP9900504A2/hu unknown
- 1996-02-01 BR BR9612470A patent/BR9612470A/pt not_active Application Discontinuation
- 1996-02-01 CZ CZ981605A patent/CZ160598A3/cs unknown
- 1996-02-01 JP JP9527525A patent/JPH11504946A/ja active Pending
- 1996-02-01 KR KR10-1998-0705074A patent/KR100347862B1/ko not_active IP Right Cessation
- 1996-02-01 WO PCT/RU1996/000028 patent/WO1997027845A1/ru not_active Application Discontinuation
- 1996-02-01 US US08/930,733 patent/US5965623A/en not_active Expired - Fee Related
- 1996-02-01 SI SI9620053A patent/SI9620053A/sl not_active IP Right Cessation
- 1996-02-01 CN CN96180161A patent/CN1213964A/zh active Pending
- 1996-02-01 SK SK655-98A patent/SK65598A3/sk unknown
- 1996-02-01 EP EP96902026A patent/EP0896819A4/en not_active Withdrawn
- 1996-02-01 GE GEAP19964288A patent/GEP20001955B/en unknown
-
1998
- 1998-04-21 LT LT98-054A patent/LT4441B/lt not_active IP Right Cessation
- 1998-05-28 LV LVP-98-126A patent/LV12177B/lv unknown
- 1998-07-30 NO NO983508A patent/NO983508D0/no unknown
- 1998-07-31 MX MX9806182A patent/MX9806182A/es unknown
- 1998-08-20 BG BG102709A patent/BG102709A/xx active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BG102709A (en) | 1999-06-30 |
| LV12177B (lv) | 1999-06-20 |
| LV12177A (lv) | 1998-12-20 |
| CN1213964A (zh) | 1999-04-14 |
| EP0896819A1 (en) | 1999-02-17 |
| LT98054A (en) | 1998-10-26 |
| AU710479B2 (en) | 1999-09-23 |
| JPH11504946A (ja) | 1999-05-11 |
| BR9612470A (pt) | 1999-07-13 |
| LT4441B (lt) | 1999-01-25 |
| NO983508L (no) | 1998-07-30 |
| RU2125446C1 (ru) | 1999-01-27 |
| SI9620053A (sl) | 1998-04-30 |
| US5965623A (en) | 1999-10-12 |
| KR19990076946A (ko) | 1999-10-25 |
| PL187564B1 (pl) | 2004-08-31 |
| PL322596A1 (en) | 1998-02-02 |
| NO983508D0 (no) | 1998-07-30 |
| KR100347862B1 (ko) | 2003-01-24 |
| HUP9900504A2 (en) | 1999-09-28 |
| CA2244985A1 (en) | 1997-08-07 |
| GEP20001955B (en) | 2000-03-05 |
| WO1997027845A1 (fr) | 1997-08-07 |
| EE9800209A (et) | 1998-12-15 |
| AU4636396A (en) | 1997-08-22 |
| MD1430B1 (ro) | 2000-03-31 |
| SK65598A3 (en) | 1998-09-09 |
| EP0896819A4 (en) | 2001-11-07 |
| CZ160598A3 (cs) | 1998-08-12 |
| UA48212C2 (uk) | 2002-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT693924E (pt) | Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos | |
| GEP20022803B (en) | Steroid Sulphatase Inhibitors | |
| CO4970836A1 (es) | Formulaciones inyectables de larga accion que contienen aceite de castor hidrogenado | |
| MX9806182A (es) | Medicamento antiglucocorticoide. | |
| KR930007444A (ko) | 4-비페닐아세트 산(bpaa)를 함유하는 제약학적 조성물 | |
| FR2635265B1 (fr) | Composition pharmaceutique intraveineuse comprenant de la cyclosporine en tant que principe actif et procede pour sa preparation | |
| DE3574928D1 (de) | Substrat zum verabreichen aktiver arzneimittel auf menschliche haut. | |
| PH30120A (en) | Stable pharmaceutical composition of fumagillol derivatives | |
| Steiger et al. | The sleep EEG and nocturnal hormonal secretion studies on changes during the course of depression and on effects of CNS-active drugs | |
| AR009231A1 (es) | Formulaciones en aerosol de formoterol. | |
| NO176082C (no) | Fremgangsmåte for fremstilling av et farmasöytisk preparat inneholdende bunazosin, for perkutan tilförsel | |
| KR940005278A (ko) | 약제학적 조성물 | |
| Dugan et al. | Regulation of hepatic β-hydroxy-β-methylglutaryl coenzyme A reductase by the interplay of hormones | |
| Sporn et al. | Platforms and networks in triterpenoid pharmacology | |
| KR970032872A (ko) | 아세틸살리실산을 함유하는 피부 손상 처치용 약물 | |
| KR930003924A (ko) | 골 소모성 질환의 치료방법 | |
| Stephens-Jarnagin et al. | The growth-supporting activity of a retinoidal benzoic acid derivative and 4, 4-difluororetinoic acid | |
| DE2345376A1 (de) | Pharmazeutische zubereitung ii | |
| Yoneshima et al. | Fosfomycin inhibits NF-κB activation in U-937 and Jurkat cells | |
| FR2690340B1 (fr) | Nouveau procédé de stabilisation des préparations pharmaceutiques liquides et les compositions pharmaceutiques ainsi stabilisées en résultant. | |
| Förstermann et al. | Thimerosal, an inhibitor of endothelial acyl-coenzyme A: lysolecithin acyltransferase, stimulates the production of a nonprostanoid endothelium-derived vascular relaxing factor | |
| US5618545A (en) | Skin-cosmetic composition | |
| Kantibiswas et al. | Effect of Picrorhiza kurroa Benth. in acute inflammation | |
| Heimberg et al. | Effect of adrenocortical and hypophyseal hormones on uptake of fat by isolated perfused liver | |
| Rakhimova et al. | Study of chronic toxicity of a collection with antidiabetic effect |